ClinicalTrials.Veeva

Menu
M

Medical Concierge Centrum Medyczne | Warsaw, Poland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Semaglutide
Vepugratinib
LY3866288
Guselkumab
Orforglipron

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron work...

Enrolling
Urinary Incontinence,Stress
Drug: Placebo
Drug: Orforglipron

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladde...

Begins enrollment this month
Urinary Bladder Neoplasms
Neoplasm Metastasis
Drug: Vepugratinib
Drug: EV

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Active, not recruiting
High-risk Non-muscle Invasive Bladder Cancer
Biological: Pembrolizumab
Biological: BCG

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
Novo Nordisk logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems